Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATATE in Liver-Dominant Metastatic Neuroendocrine Tumors
NCT04544098Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2020
- Primary completion
- Sep 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of patients who successfully complete 2 IA injections at 2 years and Objective response at 1 year. Started Sep 2020; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04544098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544098.